INCREASED EXPRESSION OF PIM2 GENE IS ASSOCIATED WITH POOR PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA.
(Abstract release date: 05/19/16)
EHA Library. Kapelko-Slowik K. 06/09/16; 132599; E1050
Assoc. Prof. Katarzyna Kapelko-Slowik
Contributions
Contributions
Abstract
Abstract: E1050
Type: Eposter Presentation
Background
PIM2 gene belongs to PIM family, which encodes serine/threonine kinases involved in cell survival and apoptosis. PIM2 gene is implicated in many neoplasms including solid tumors and acute myeloid leukemia. The relation between expression of PIM2 gene and course of chronic lymphocytic leukemia`s (CLL) as well as outcome has not been fully defined.
Aims
The aim of the study was to evaluate the role of PIM2 gene as a marker for CLL malignancy and the importance of PIM2 gene expression as a prognostic factor in CLL.
Methods
Sixty-seven patients, 35 females and 32 males, aged 49-90 years (median age was 66 years) with de novo CLL were enrolled in the study. Thirty-two patients reached complete remission (CR). Bone marrow samples were collected in all patients at the time of diagnosis, whereas only samples with monoclonal lymphoid cells for more than 80% of total cellularity were assessed. In 16 patients bone marrow in CR phase was examined. The control group consisted of 14 healthy individuals. The expression of PIM2 gene was analyzed by Taq Man RQ-PCR assay and PIM2 protein was detected by Western blot. All statistical analyses were performed using Statistica software.
Results
Median PIM2 gene expression in CLL patients was significantly higher than in control group. CLL patients with high expression levels of PIM2 gene (above the median) had significantly shorter progression free survival (PFS) than patients with low PIM2 expression (p=0.001). In addition, it was found that patients who achieved CR, had significantly lower expression of PIM2 gene than patients with no CR (p=0.002). Importantly, elevated PIM2 gene expression assessed initially, was restored to normal level in all patients in CR. Moreover, the overexpression of the PIM2 kinase was detected in CLL patients in contrast to controls. PIM2 expression in correlation to CLL Rai stages was evaluated also and it was noted that PIM2 expression in stages IV and III was higher than in both stages I and II (p=0.002). Moreover, CLL patients with rapid lymphocyte doubling time (LDT) (<12 months) shown higher PIM2 expression than patients with lower LDT (≥12 months), p=0.003. Positive correlation between PIM2 gene expression and the percentage of malignant lymphocytes with ZAP70 expression was found (r2=0.3214 p=0.01).
Conclusion
We showed that increased expression of PIM2 gene in CLL cells is associated with poor prognosis and resistance to chemotherapy in CLL patients.
Session topic: E-poster
Keyword(s): B-CLL, Oncogene
Type: Eposter Presentation
Background
PIM2 gene belongs to PIM family, which encodes serine/threonine kinases involved in cell survival and apoptosis. PIM2 gene is implicated in many neoplasms including solid tumors and acute myeloid leukemia. The relation between expression of PIM2 gene and course of chronic lymphocytic leukemia`s (CLL) as well as outcome has not been fully defined.
Aims
The aim of the study was to evaluate the role of PIM2 gene as a marker for CLL malignancy and the importance of PIM2 gene expression as a prognostic factor in CLL.
Methods
Sixty-seven patients, 35 females and 32 males, aged 49-90 years (median age was 66 years) with de novo CLL were enrolled in the study. Thirty-two patients reached complete remission (CR). Bone marrow samples were collected in all patients at the time of diagnosis, whereas only samples with monoclonal lymphoid cells for more than 80% of total cellularity were assessed. In 16 patients bone marrow in CR phase was examined. The control group consisted of 14 healthy individuals. The expression of PIM2 gene was analyzed by Taq Man RQ-PCR assay and PIM2 protein was detected by Western blot. All statistical analyses were performed using Statistica software.
Results
Median PIM2 gene expression in CLL patients was significantly higher than in control group. CLL patients with high expression levels of PIM2 gene (above the median) had significantly shorter progression free survival (PFS) than patients with low PIM2 expression (p=0.001). In addition, it was found that patients who achieved CR, had significantly lower expression of PIM2 gene than patients with no CR (p=0.002). Importantly, elevated PIM2 gene expression assessed initially, was restored to normal level in all patients in CR. Moreover, the overexpression of the PIM2 kinase was detected in CLL patients in contrast to controls. PIM2 expression in correlation to CLL Rai stages was evaluated also and it was noted that PIM2 expression in stages IV and III was higher than in both stages I and II (p=0.002). Moreover, CLL patients with rapid lymphocyte doubling time (LDT) (<12 months) shown higher PIM2 expression than patients with lower LDT (≥12 months), p=0.003. Positive correlation between PIM2 gene expression and the percentage of malignant lymphocytes with ZAP70 expression was found (r2=0.3214 p=0.01).
Conclusion
We showed that increased expression of PIM2 gene in CLL cells is associated with poor prognosis and resistance to chemotherapy in CLL patients.
Session topic: E-poster
Keyword(s): B-CLL, Oncogene
Abstract: E1050
Type: Eposter Presentation
Background
PIM2 gene belongs to PIM family, which encodes serine/threonine kinases involved in cell survival and apoptosis. PIM2 gene is implicated in many neoplasms including solid tumors and acute myeloid leukemia. The relation between expression of PIM2 gene and course of chronic lymphocytic leukemia`s (CLL) as well as outcome has not been fully defined.
Aims
The aim of the study was to evaluate the role of PIM2 gene as a marker for CLL malignancy and the importance of PIM2 gene expression as a prognostic factor in CLL.
Methods
Sixty-seven patients, 35 females and 32 males, aged 49-90 years (median age was 66 years) with de novo CLL were enrolled in the study. Thirty-two patients reached complete remission (CR). Bone marrow samples were collected in all patients at the time of diagnosis, whereas only samples with monoclonal lymphoid cells for more than 80% of total cellularity were assessed. In 16 patients bone marrow in CR phase was examined. The control group consisted of 14 healthy individuals. The expression of PIM2 gene was analyzed by Taq Man RQ-PCR assay and PIM2 protein was detected by Western blot. All statistical analyses were performed using Statistica software.
Results
Median PIM2 gene expression in CLL patients was significantly higher than in control group. CLL patients with high expression levels of PIM2 gene (above the median) had significantly shorter progression free survival (PFS) than patients with low PIM2 expression (p=0.001). In addition, it was found that patients who achieved CR, had significantly lower expression of PIM2 gene than patients with no CR (p=0.002). Importantly, elevated PIM2 gene expression assessed initially, was restored to normal level in all patients in CR. Moreover, the overexpression of the PIM2 kinase was detected in CLL patients in contrast to controls. PIM2 expression in correlation to CLL Rai stages was evaluated also and it was noted that PIM2 expression in stages IV and III was higher than in both stages I and II (p=0.002). Moreover, CLL patients with rapid lymphocyte doubling time (LDT) (<12 months) shown higher PIM2 expression than patients with lower LDT (≥12 months), p=0.003. Positive correlation between PIM2 gene expression and the percentage of malignant lymphocytes with ZAP70 expression was found (r2=0.3214 p=0.01).
Conclusion
We showed that increased expression of PIM2 gene in CLL cells is associated with poor prognosis and resistance to chemotherapy in CLL patients.
Session topic: E-poster
Keyword(s): B-CLL, Oncogene
Type: Eposter Presentation
Background
PIM2 gene belongs to PIM family, which encodes serine/threonine kinases involved in cell survival and apoptosis. PIM2 gene is implicated in many neoplasms including solid tumors and acute myeloid leukemia. The relation between expression of PIM2 gene and course of chronic lymphocytic leukemia`s (CLL) as well as outcome has not been fully defined.
Aims
The aim of the study was to evaluate the role of PIM2 gene as a marker for CLL malignancy and the importance of PIM2 gene expression as a prognostic factor in CLL.
Methods
Sixty-seven patients, 35 females and 32 males, aged 49-90 years (median age was 66 years) with de novo CLL were enrolled in the study. Thirty-two patients reached complete remission (CR). Bone marrow samples were collected in all patients at the time of diagnosis, whereas only samples with monoclonal lymphoid cells for more than 80% of total cellularity were assessed. In 16 patients bone marrow in CR phase was examined. The control group consisted of 14 healthy individuals. The expression of PIM2 gene was analyzed by Taq Man RQ-PCR assay and PIM2 protein was detected by Western blot. All statistical analyses were performed using Statistica software.
Results
Median PIM2 gene expression in CLL patients was significantly higher than in control group. CLL patients with high expression levels of PIM2 gene (above the median) had significantly shorter progression free survival (PFS) than patients with low PIM2 expression (p=0.001). In addition, it was found that patients who achieved CR, had significantly lower expression of PIM2 gene than patients with no CR (p=0.002). Importantly, elevated PIM2 gene expression assessed initially, was restored to normal level in all patients in CR. Moreover, the overexpression of the PIM2 kinase was detected in CLL patients in contrast to controls. PIM2 expression in correlation to CLL Rai stages was evaluated also and it was noted that PIM2 expression in stages IV and III was higher than in both stages I and II (p=0.002). Moreover, CLL patients with rapid lymphocyte doubling time (LDT) (<12 months) shown higher PIM2 expression than patients with lower LDT (≥12 months), p=0.003. Positive correlation between PIM2 gene expression and the percentage of malignant lymphocytes with ZAP70 expression was found (r2=0.3214 p=0.01).
Conclusion
We showed that increased expression of PIM2 gene in CLL cells is associated with poor prognosis and resistance to chemotherapy in CLL patients.
Session topic: E-poster
Keyword(s): B-CLL, Oncogene
{{ help_message }}
{{filter}}